Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols

Leukemia. 2013 Sep;27(9):1936-9. doi: 10.1038/leu.2013.92. Epub 2013 Mar 29.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Child
  • Child, Preschool
  • Chromosome Aberrations
  • Female
  • Gene Amplification*
  • Gene Deletion*
  • Humans
  • Ikaros Transcription Factor / genetics*
  • Infant
  • Karyotype
  • Male
  • PAX5 Transcription Factor / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Prognosis

Substances

  • IKZF1 protein, human
  • PAX5 Transcription Factor
  • PAX5 protein, human
  • Ikaros Transcription Factor